Evidence map›Paper›PMID 39911953›Full record

ArticleInternational journal of cardiology. Congenital heart disease2025

Right heart reverse remodeling:

Tommaso Recchioni, Giovanna Manzi, Alexandra Mihai, Francesca Ileana Adamo, Annalisa Caputo, Domenico Filomena, Giorgia Serino, Silvia Papa, Nadia Cedrone, Carmine Dario Vizza and 1 more

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cardiology. Congenital heart disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tommaso RecchioniDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Giovanna ManziDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Alexandra MihaiDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Francesca Ileana AdamoDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Annalisa CaputoDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Domenico FilomenaDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Giorgia SerinoDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Silvia PapaDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Nadia CedroneUnità di Medicina Interna, Ospedale S. Pertini, Rome, Italy.
Carmine Dario VizzaDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Roberto BadagliaccaDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary arterial hypertension (PAH) is characterized by pulmonary vascular remodeling and arterial narrowing, leading to a progressive rise in right ventricular (RV) afterload and poor survival outcomes. PAH prognosis largely depends on RV remodeling and function: when the increased afterload exceeds the RV's adaptive capacity, ventricular-arterial uncoupling occurs, ultimately causing right heart failure and death. In this clinical setting the primary treatment goal is to achieve low mortality risk and right heart reverse remodeling (RHRR). Unfortunately, the definition of RHRR vary across studies and imaging modalities (echocardiography or Cardiac Magnetic Resonance). The likelihood of RHRR increases with a significant reduction in pulmonary vascular resistance (PVR) from baseline, ideally by at least 50 %. Evidence supports initial triple therapy, including parenteral prostanoids, as the most effective approach to reduce PVR enough to facilitate RHRR and thus achieve the low-risk status.

Indexed as

Cardiac magnetic resonanceEchocardiographyPulmonary arterial hypertensionRight heart catheterizationRight heart reverse remodeling

Identifiers

PMID39911953
PMCPMC11795067

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.